Date Name Title Filing Type Shares Traded Price Total Held
May 06, 2013
Director, President Regeneron Laboratori
Director, President Regeneron Laboratori Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 192,308 -- --
Dec 15, 2003
Director, EVP, CSO, & Pres Regn Res Labs
Director, EVP, CSO, & Pres Regn Res Labs Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 192,308 -- 192,308
Feb 11, 2014
Director, President Regeneron Laboratori
Director, President Regeneron Laboratori Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 189,463 $9.49 1,257,806
Feb 11, 2014
Director, President Regeneron Laboratori
Director, President Regeneron Laboratori Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 189,463 -- --
Dec 15, 2004
Director, EVP, CSO, & Pres Regn Res Labs
Director, EVP, CSO, & Pres Regn Res Labs Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 189,463 -- 189,463
Oct 30, 2015
Director, President Regeneron Laboratori
Director, President Regeneron Laboratori Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 182,818 $11.64 682,818
Oct 30, 2015
Director, President Regeneron Laboratori
Director, President Regeneron Laboratori Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 182,818 -- --
Dec 19, 2005
Director, EVP, CSO, & Pres Regn Res Labs
Director, EVP, CSO, & Pres Regn Res Labs Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 182,818 -- 182,818
Aug 03, 2017
Director, President and CSO
Director, President and CSO Form 4 Bona fide gift 176,223 -- 176,223
Aug 03, 2017
Director, President and CSO
Director, President and CSO Form 4 Bona fide gift 176,223 -- 155,406

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.